Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: A pilot study

Bone Marrow Transplantation

Volumn 22, Issue 12, 1998, Pages 1153-1158

  Blaise, D ^a   Jourdan, E ^b   Michallet, M ^c   Jouet, J P ^d   Boiron, J M ^e   Michel, G ^f   Faucher, C ^a   Fegueux N ^b   Schuller, M P ^g   Badri, N ^g   Chabannon, C ^a   Maraninchi, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^g SANOFI   (France)

Author keywords

Allogeneic; Blood cell transplantation; G CSF; Lenograstim

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; CYCLOSPORIN A; HLA ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE PAIN; CANCER SURVIVAL; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; PROBABILITY; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

EID: 0032439390     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701505     Document Type: Article

References (34)

1. Welte K, Gabrilove J, Bronchud MH et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907-1929.
2. Sheridan W, Begley C, Juttner C et al. Effect on peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-643.
3. Faucher C, Le Coroller AG, Biaise D et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow autotransplantation: clinical assessment and cost effectiveness. Bone Marrow Transplant 1994; 14: 895-901.
4. Hartmann O, Le Corroller AG, Biaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600-607.
5. Gratwohl A, Hermans J, Baldomero H for the European Group for Blood and Marrow Transplantation (EBMT). Blood and marrow Transplantation activity in Europe 1995. Bone Marrow Transplant 1997; 19: 407-419.
6. Anderlini P, Korbling M, Dale D et al. Allogeneic blood stem cell transplantation: consideration for donors. Blood 1997; 90: 903-908.
7. Bensinger WI, Weaver CH, Appelbaum F et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor (rhG-CSF). Blood 1995; 85: 1655-1658.
8. Körbling M, Prezpiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
9. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
10. Frampton J. Lenograstim: a review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings. Drugs 1995; 49: 767-793.
11. Blaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan vs cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse (see comments). Blood 1992; 79: 2578-2582.
12. Blaise D, Olive D, Michallet M et al. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995; 345: 1144-1146.
13. Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan vs cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Grafts (SFGM). Blood 1995; 85: 2263-2268.
14. Chabannon C, Lafage M, Mozziconacci MJ et al. Early establishment of chimerism in the B and T lymphoid lineages after transplantation of allogeneic mobilized blood cells in leukemic patients. Transplantation 1997; 63: 1646-1652.
15. Thomas E, Storb R, Clift R et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832-843, 895-902.
16. Cahn JY, Bordigoni P, Souillet G et al. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of 62 patients. Bone Marrow Transplant 1991; 7: 1-4.
17. Santos GW, Tutshka PJ, Brookmeyer R et al. Marrow transplantation for acute non-lymphoblastic leukemia after treatment with busulfan and cyclosphosphamide. New Engl J Med 1983; 309: 1347-1353.
18. Vey N, De Prijck B, Faucher C et al. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies. Bone Marrow Transplant 1996; 18: 495-499.
19. Chao NJ, Deeg HJ. In vivo prevention and treatment of GVHD. In: Ferrara JLM, Deeg HJ, Burakoff SJ (eds). Graft-versus-Host Disease. Marcel Dekker: New York, 1997, pp 639-666.
20. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
22. Anderlini P, Lauppe J, Przepiorka D et al. Peripheral blood stem cells apheresis in normal donors: feasibility and yield of second collections. Br J Haematol 1997; 96: 415-417.
23. + peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996; 88: 4132-4138.
24. + Thy-1) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
25. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
26. + cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Haematother 1996; 5: 663-670.
27. - bone marrow cells after allogeneic peripheral blood transplantation with a long follow-up. Bone Marrow Transplant 1998; 21: 189-194.
28. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
29. Pan L, Delmonte J Jr, Jalonen C et al. Pre-treatment of donor mice with granulocyte colony-stimulating factor polarises donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-4429.
30. Miller JS, Prosper F, McCullar V. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilised peripheral blood progenitor cell collections. Blood 1997; 90: 3098-3105.
31. Oziel-Taieb S, Faucher-Barbey C, Chabannon C et al. Early and fatal immune haemolysis after so-called 'minor' ABO-incompatible peripheral blood stem cell allotransplantation. Bone Marrow Transplant 1997; 19: 1155-1156.
32. Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow transplantation vs figrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.
33. Faucher C, Fortanier C, Protière C et al. Comparison of peripheral blood progenitor cells (PBPC) and bone marrow (BM) allogeneic transplantation: clinical and cost-effectiveness study. Blood 1995; 86 (Suppl.): 385 (Abstr. 1528).
34. + blood cells. Blood 1996; 87: 4903-4909.